Oral Presentation:
Body Composition Changes on Darunavir/Ritonavir (DVR/r) + either Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) as First-Line Antiretroviral Therapy, presented by Jose I. Bernardino for the NEAT 001/ANSR 143 Study Group. O-4/45. PRESENTATION WEBCAST

54th ICAAC, Washington DC 5-9 September 2014:

Oral presentation:
Changes in Bone Mineral Density (BMD) over 96 weeks on Darunavir/Ritonavir (DRV/r) + Raltegravir (RAL) or Darunavir/Ritonavir + Tenofovir/Emtricitabine (TDF/FTC). NEAT 001/ ANRS. BMD sub-study. JI Bernadino, A Mocroft, PW Mallon, C Wallet, P REiss, C Katkama, S de Wit, A Antinori,J Gerstoft, J González-Garcia, L Palmisano, EC George, J Saillard, F Raddi, JR Arribas.  PRESENTATION